【摘要】 目的:观察氟达拉滨单药(F方案)或联合环磷酰胺(FC方案)治疗慢性淋巴细胞白血病的疗效及不良反应观察。方法:2006-2012年33例慢性淋巴细胞白血病患者分为3组,F组11例,FC组11例,CHOP组11例,研究含氟达拉滨的治疗方案与传统CHOP方案对慢性淋巴细胞白血病的疗效及不良反应,同时研究F方案与FC方案在治疗慢性淋巴细胞白血病方面的疗效及不良反应。结果:F和FC方案与CHOP方案相比,完全缓解率(CR)提高,总有效率(OR)提高,差异具有统计学意义(P<0.05)。三种方案不良反应在血液学改变方面及在非血液学方面,差异无统计学意义(P>0.05)。结论:含有氟达拉滨的方案治疗慢性淋巴细胞白血病疗效优于传统的CHOP一线治疗方案,氟达拉滨与环磷酰胺联合优于氟达拉滨单药治疗,不良反应无明显增加。更多还原

【Abstract】 Objective:To observe the therapeutic effects and adverse reactions of fludarabine or fludarabine combined cyclophosphamide in chronic lymphocytic leukemia(CLL).Method:33 patients with CLL were divided into three treatment group,each group was given fludarabine or fludarabine combined cyclophosphamide or CHOP regimen.Compared the the rate of complete remission(CR),overall remission(OR)and adverse reactions.Result:F and FC regimen resulted in significantly were higher CR rate than that in CHOP regimen(P <0.05).The rate of complete remission(CR)of FC regimen was higher than that of fludarabine regimen.No significant difference was found in side effects between three regimens(P >0.05).Conclusion:Fludarabine in chronic lymphocytic leukemia(CLL)has a much better therapeutic effect than CHOP regimen.FC regimen can give higher CR rate as compared with F regimen.更多还原